ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2025
Polarization-Sensitive Holotomography for Multidimensional Label-Free Imaging and Characterization of Lipid Droplets in Cancer Cells.
Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Physics-paired stimulated Raman scattering microscopy enables label-free phenotyping of lipid droplets 3D motility in live cells.Light, science & applications · 2026Article
- Polarization-Sensitive Holotomography for Multidimensional Label-Free Imaging and Characterization of Lipid Droplets in Cancer Cells.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Lipid droplets (LDs) are key markers of cellular metabolism, often altered in cancer. While holotomography enables 3D, label-free imaging of LDs via refractive index, it relies on complex thresholding and lacks biochemical specificity. Here, polarization-sensitive holotomography (PS-HT), which leverages the intrinsic birefringence of LDs for high-contrast, selective identification with a fixed near-zero threshold is presented. Using prostate cell models (healthy PNT2 and cancer PC3), PS-HT is validated against fluorescence microscopy and holotomography, showing that it enables accurate quantification of birefringence, LD volume, dry mass, molecular organization, and spatial distribution. Cancer cells show significantly higher birefringence after glucose treatment, reflecting enhanced lipid accumulation. PS-HT, combined with principal component analysis, achieves near-perfect classification of cancer versus healthy cells, establishing it as a robust, label-free tool for studying lipid metabolism and cancer diagnostics.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.